Synergistic Cancer Therapeutic Systems

The present invention integrates OPCML-based cancer therapy with distinct technologies such as AI, IoT, blockchain, and nanomaterials to create a more powerful system for personalized cancer treatment, research, and data management.

Cancer is a leading cause of mortality worldwide, and current treatment options often have limited efficacy and significant side effects. The original patent disclosed the use of OPCML fragments for cancer therapy, but it lacked the scalability, precision, and security offered by modern technologies. The new inventive concept addresses these limitations by combining OPCML fragments with AI-driven recommendation engines, IoT-enabled wearable devices, blockchain-based data management platforms, and nanomaterial-based delivery vehicles.

The synergistic system comprises a database of OPCML fragments, which can be fused to non-OPCML polypeptides for enhanced efficacy. The AI-driven recommendation engine selects optimal treatment regimens based on patient-specific genomic data and OPCML fragment efficacy. IoT-enabled wearable devices enable real-time monitoring of treatment response and patient health, while the blockchain-based data management platform ensures secure and transparent sharing of research data and clinical trial results. The nanomaterial-based delivery vehicle facilitates targeted and controlled release of the OPCML fragment in cancer cells. This integrated system enables personalized cancer treatment, improves treatment outcomes, and accelerates research and development.

The new claims introduce the concept of integrating OPCML-based cancer therapy with distinct technologies, which is novel and non-obvious compared to the original patent. The use of AI, IoT, blockchain, and nanomaterials in conjunction with OPCML fragments provides a synergistic effect that enhances the efficacy, precision, and security of cancer treatment and research.

Alternative embodiments may include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations may involve the integration of OPCML fragments with other emerging technologies, such as CRISPR gene editing or synthetic biology.

The synergistic cancer therapeutic system has significant commercial potential in the pharmaceutical, biotechnology, and healthcare industries. It can be used for personalized cancer treatment, research, and data management, and has the potential to improve treatment outcomes, reduce healthcare costs, and accelerate the development of new cancer therapies.